Glaxo loses to Teva on Seretide in Ireland

Reuters notes: The ruling from the Commercial Court in Dublin is a victory for Teva Pharmaceutical Industries, whose Ivax unit had challenged the combination patent for Seretide (Advair in the US). The patent relates to the combination of the active ingredients salmeterol and fluticasone propionate, and expires in 2013. This ruling applies only in Ireland and Glaxo has other patents. Would one say that this was a "bad" patent, because a court found it invalid?

See also:

http://ipbiz.blogspot.com/2006/07/hubers-in-defense-of-big-pharma.html